OTC News Archive

Office of Technology Commercialization at UT Austin licenses unique cancer detection method

Remicalm develops optical detection method

July 10, 2006

The Office of Technology Commercialization (OTC) at The University of Texas at Austin has signed a licensing agreement with Remicalm LLC to commercialize a unique method of detecting cancer optically.

The agreement provides the Texas-based company with worldwide rights to 19 issued patents and seven additional patent applications and provisional patents for use in the detection of cancer and precancerous cells in the human body.

The research team—led by Dr. Rebecca Richards-Kortum, formerly at The University of Texas at Austin in the Department of Biomedical Engineering and the Cockrell Family Chair in Engineering and Distinguished Teaching Professor, Dr. Michele Follen at The University of Texas M. D. Anderson Cancer Center, and Dr. Calum MacAulay at The British Columbia Cancer Agency—has developed a method of identifying cancerous and precancerous cells in human tissue through the use of optical fluorescence and reflectance. It provides the foundation for Remicalm’s innovative approach to the detection of cancer.

“This state-of-the-art technology could prove to be one of the most exciting breakthroughs in cancer detection to date,” Hugh Hyde, Remicalm’s chief executive, said. “Optical detection can be used by healthcare providers to deliver quick, painless non-invasive testing.”

“This endeavor is a great example of collaboration among world-ranking research facilities—The University of Texas at Austin, The University of Texas M. D. Anderson Cancer Center, and The British Columbia Cancer Agency,” said Neil Iscoe, director of the OTC at The University of Texas at Austin. “All three institutions have the expertise and the resources which developed technology that will improve the outlook for cancer detection on a global basis.”